Exploring the pathogenesis of pulmonary vascular disease

Area of Science:

• Cardiopulmonary Medicine
• Vascular Biology
• Epigenetics

Background:

• Pulmonary hypertension (PH) is a disorder of the lung vasculature, increasing pulmonary vascular resistance and causing right ventricular dysfunction.
• Group 1 PH, or pulmonary arterial hypertension (PAH), involves direct alterations to the pulmonary arteries.
• PAH is a multifactorial disease with increasing incidence, prevalence, morbidity, and mortality, lacking a cure.

Purpose of the Study:

• To review the pathological mechanisms of PAH.
• To focus on the role of epigenetic modifications in PAH development and progression.
• To highlight potential novel therapeutic targets for PAH.

Main Methods:

• Literature review of pathological mechanisms in PAH.
• Focus on epigenetic modifications including DNA methylation, histone modifications, and microRNA dysregulation.
• Analysis of the contribution of these modifications to PAH pathogenesis.

Main Results:

• Epigenetic modifications, including DNA methylation, histone modifications, and microRNA dysregulation, play significant roles in PAH.
• These epigenetic changes contribute to the complex pathophysiology of PAH.
• Understanding these mechanisms is crucial for identifying new therapeutic strategies.

Conclusions:

• Epigenetic modifications are key drivers in the development and progression of pulmonary arterial hypertension.
• Further research into these epigenetic mechanisms can unveil novel therapeutic targets.
• This understanding may lead to innovative treatment strategies for PAH patients.